Journal List > Korean Diabetes J > v.32(5) > 1002244

TOOLS
Lee, Jeong, Choi, Kim, Lee, Kang, Jeon, and Oh: Association Study of the Peroxisome Proliferators-Activated Receptor γ2 Pro12Ala Polymorphism with Diabetic Nephropathy
Original Article
Korean Diabetes Journal

Korean Diabetes Journal 2008; 32(5): 402-408.

Published online: 31 October 2008

DOI: https://doi.org/10.4093/kdj.2008.32.5.402

Association Study of the Peroxisome Proliferators-Activated Receptor γ2 Pro12Ala Polymorphism with Diabetic Nephropathy

Kyu-Ho Lee, Hee seog Jeong, Khan Young Choi, Hyun Kim, Dal-Sic Lee, Ji Young Kang, Hyun Jeong Jeon, Tae Keun Oh

Department of Internal Medicine, Chungbuk National University College of Medicine, Korea.

Received 14 July 2008       Accepted 13 October 2008

Copyright © 2008 Korean Diabetes Association

Abstract

Background

Peroxisome proliferators-activated receptor γ (PPARγ) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors and known to play a role in regulating the expression of numerous genes involved in lipid metabolism, metabolic syndrome, inflammation, and atherosclerosis. The PPARγ2 Pro12Ala polymorphism has recently been shown to be associated with diabetic nephropathy. In this study, we evaluated the relationship between PPARγ2 Pro12Ala polymorphism and type 2 diabetic nephropathy whose duration of diabetes was over 10 years.

Methods

We conducted a case-control study, which enrolled 367 patients with type 2 diabetes. Genotyping of PPARγ2 Pro12Ala polymorphism was performed using polymerase chain reaction followed by digestion with Hae III restriction enzyme.

Results

The genotype or allele frequencies of PPARγ2 Pro12Ala polymorphism were not significantly different in diabetic patients with or without diabetic nephropathy. The genotype frequencies in terms of diabetic retinopathy and macrovascular complications such as coronary artery disease or stroke were not different either. Interestingly, nephropathy patients with Ala/Pro genotype showed lower C-peptide levels than those of Pro/Pro genotype.

Conclusion

Our results suggest that PPARγ2 Pro12Ala polymorphism is not associated with diabetic nephropathy in type 2 diabetic patients.

Keywords: Diabetic nephropathy, PPARγ2 Pro12Ala polymorphism, Type 2 diabetes

Figures and Tables

Fig. 1
Genotyping of PPAR-γ2 gene. The amplified PCR products were digested with the restriction enzyme Hae III. The Pro12 alleles gives one 132-and 22-bp fragments whereas the Ala12 alleles gives one 155-bp fragment. Lane 1,3,5,6,7,8: Pro/Pro genotype, Lane 2, 4: Ala/Pro genotype.
kdj-32-402-g001
Table 1
Clinical characteristics of patients with type 2 diabetes with or without nephropathy
kdj-32-402-i001

Data are means ± SD. BMI, body mass index; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; PP2, postprandial 2 hours blood sugar; SBP, systolic blood pressure.

Table 2
Distribution of PPARγ2 Pro12Ala genotypes and alleles in patients with or without DM nephropathy
kdj-32-402-i002

PPAR, Peroxisome proliferators-associated receptor. HWP, Hardy-Weinberg equilibrium.

Table 3
PPARγ2 Pro12Ala genotypes according to diabetic retinopathy and microvascular complications
kdj-32-402-i003

PPAR, Peroxisome proliferators-associated receptor.

Table 4
Clinical characteristics of the PPARγ2 Pro12Ala genotypes in patients with DM nephropathy
kdj-32-402-i004

Data are means ± SD. BMI, body mass index; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; PP2, postprandial 2 hours blood sugar; SBP, systolic blood pressure.

References

1. Desvergne B, Wahli W. Peroxisome proliferators activated receptors; Nuclear control of metabolism. Endocr Rev. 1999. 20:649–688.
2. Rosen ED, Spiegelman BM. PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001. 276:37731–37734.
3. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Wilson TM, Kliewer SA. An antidabetic thiazolidione is high affinity ligand for peroxisome proliferators-activated receptor (PPAR). J Biol Chem. 1995. 270:12953–12956.
4. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V. Pro12Ala substitution in the peroxisome proliferators-activated receptor-2 is not associated with type 2 diabetes. Diabetes. 1999. 48:1466–1468.
5. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferators-activated receptor and DM. Biocheml Biophys Res Commun. 1999. 254:450–453.
6. Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR, Beamer BA, Charpentier G, Guy-Grand B, Froguel P, Vaisse C. The Pro115Gln and pro12Ala PPAR gene mutations in obesity and type 2 diabetes. Intl J Obes Relat Metab Disord. 2000. 24:391–393.
7. Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol. 1994. 266:H2568–H2572.
8. Groemping Y, Rittinger K. Activation and assembly of the NADPH oxidase: A structural perspective. Biochem J. 2005. 386:401–416.
9. Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant. 2006. 21:2399–2405.
10. Ma J, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects agonist nondiabetic glomerulosclerosis in rats. Kidney Int. 2001. 59:1899–1910.
11. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006. 70:1223–1233.
12. Izzedine H, Launay-Vacher V, Buhaescu I, Heurtier A, Baumelou A, Deray G. PPAR-gamma-agonists renal effects. Minerva Urol Nefol. 2005. 57:247–260.
13. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998. 20:284–287.
14. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E. Peroxisome proliferator-activated receptor-γ2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. Diabetes. 2002. 51:2653–2657.
15. Caramori ML, Canari LH, Costa LA, Gross JL. The human Peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes. 2003. 52:3010–3013.
16. Jorsal A, Tarnow L, Lajer M, Ek J, Hansen T, Pedersen O, Parving HH. The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. Mol Genet Metab. 2008. 94:347–351.
17. Moon MK, Cho YM, Jung HS, Park YJ, Yoon KH, Sung YA, Park BL, Lee HK, Park KS, Shin HD. Genetic polymorphisms in peroxisome proliferator-activated receptor gamma are associated with Type 2 diabetes mellitus and obesity in the Korean population. Diabet Med. 2005. 22:1161–1166.
18. Yamamoto J, Kageyama S, Nemoto M, Sasaki T, Sakurai T, Ishibashi K, Mimura A, Yokota K, Tajima N. PPARgamma2 pro12Ala polymorphism and insulin resistance in Japanese hypertensive patients. Hypertens Res. 2002. 25:25–29.
19. Oh EY, Min KM, Chung JH, Min YK, Lee MS, Kim KW, LEE MK. Significance of pro12ala mutation in peroxisome proliferator-activated receptor-γ2 in Korean diabetic and obese subjects. J Clin Endoclinol Metab. 2000. 85:1801–1804.
20. Oh SJ, Kang SY, Kim DY, Kim YS, Yang IM, Paeng JR. Polymorphisms of PPARγ2 gene in patients with type 2 diabetes mellitus and obesity. Korean J Med. 2000. 59:132–141.
21. Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hegele RA, Hanley AJ. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications. 2007. 21:166–171.
TOOLS
Similar articles